The Swiss Market Index closed at a record 13,847 points on Friday, propelled by a powerful rally in pharmaceutical heavyweights that has added over CHF 120 billion in market capitalisation to the Swiss exchange since the start of the quarter. The milestone marks the first time the blue-chip index has breached the 13,800 level, capping a remarkable period of outperformance for European equities.
Pharma Leads the Charge
Novartis and Roche, which together account for nearly 40 percent of the SMI’s weighting, have been the primary engines of the advance. Novartis shares have gained 18 percent year-to-date following strong clinical data for its oncology pipeline, while Roche has climbed 14 percent on the back of its immunotherapy breakthrough announcement and better-than-expected diagnostics revenues.
“The SMI’s composition has always given it a defensive character, but what we are seeing now is genuine growth momentum from the pharmaceutical sector. These are not just safe-harbour holdings — they are companies delivering transformational therapies that the market is revaluing upward.” — Sarah Ischer, Head of Swiss Equities, Vontobel Asset Management
Beyond pharma, the index has been supported by resilient performances from Nestlé, which has benefited from pricing power in emerging markets, and from the financial sector, where UBS has rallied on the back of strong wealth management inflows linked to the Swiss franc’s safe-haven appeal.
Sustainability of the Rally
Market observers are divided on whether the SMI can sustain its upward trajectory. Bulls point to Switzerland’s unique combination of innovative companies, stable governance, and a currency that attracts international capital. Bears counter that valuations are becoming stretched, with the index trading at 22 times forward earnings — well above its ten-year average of 17.5 times.
Foreign investor participation has been a notable feature of the rally. Data from SIX Swiss Exchange shows that international holdings of SMI constituents have risen to 68 percent, the highest proportion on record. Much of this inflow has come from Asian institutional investors diversifying away from US-concentrated portfolios.
The Swiss National Bank’s quarterly investment report, due next week, will be closely watched for signals on monetary policy direction. Any hint of rate adjustments could introduce volatility, though most analysts expect the SNB to hold rates steady given the current balance between growth and inflation. For now, the SMI’s record run continues to underscore Switzerland’s status as one of the world’s premier equity markets.
